Premaitha Health has signed a distribution agreement with a company in Greece to provide its non-invasive prenatal screening test (NIPT), branded IONA, to laboratories in the region.
Premaitha has struck the deal with Antisel SA, a distributor of scientific products in Greece, for the test which detects the risk of a fetus being affected by Down’s Syndrome and other serious genetic conditions such at Patau’s Syndrome and and Edwards Syndrome. The test is carried out by analysing fetal DNA from a sample of maternal blood. As the first and only CE-marked (European approved) test of its kind, the IONA test enables clinical laboratories to run their own in-house service without having to send blood samples to central labs in the USA or China with a wait for results of up to 14 days.
Premaitha chief executive Dr Stephen Little said: “This valuable partnership will enable us to provide the IONA® test to hospitals throughout the country and we look forward to working with the Antisel team to help support clinical teams in setting up their own NIPT screening service.”
See the article in full at TheBusinessDesk.com